Pharmaceutical composition for preventing or treating obesity or non-alcoholic fatty liver containing Polygalin C as active ingredient
View Patent ↗The present invention relates to a pharmaceutical composition for preventing or treating obesity, wherein the pharmaceutical composition contains Polygalin C as an active ingredient. The Polygalin C not only reduces the accumulation of lipids by inhibiting the differentiation of preadipocytes into adipocytes, but also inhibits adipose tissue generation factors and adipogenic factors and modulates AMPK/ACC and MAPK/Akt signaling pathways to inhibit the differentiation of adipocytes, and thus can treat obesity more effectively. In addition, the present invention inhibits adipogenic factors and inflammatory factors in a free fatty acid-induced non-alcoholic steatohepatitis (NASH) cell model, and thus can effectively treat and prevent non-alcoholic fatty liver disease (NAFLD) including hepatic steatosis and non-alcoholic steatohepatitis.
1 . A method of reducing body fat, comprising:
administering a health functional food comprising Polygalin C as an active ingredient to a subject, wherein the Polygalin C inhibits differentiation of preadipocytes into adipocytes, thereby suppressing lipid accumulation; downregulates peroxisome proliferator-activated receptor γ(PPARγ), CCAAT/enhancer-binding protein α (C/EBPα) sterol regulatory element-binding protein 1c (SREBP1c), and fatty acid synthase (FAS), activates AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC); and inhibits mitogen-activated protein kinase (MAPK) and protein kinase B (Akt) signaling pathways in the subject.
2 . The method of claim 1 , wherein the body fat is selected from obesity caused by a high-fat diet or body fat caused by hormonal deficiency due to menopause.
3 . The method of claim 1 , wherein the Polygalin C is contained in an amount of 0.01 to 50 parts by weight with respect to a total of 100 parts by weight of the health functional food.
4 . A method for treating non-alcoholic fatty liver, comprising:
administering a pharmaceutical composition comprising Polygalin C as an active ingredient to a subject, wherein the Polygalin C inhibits differentiation of preadipocytes into adipocytes, thereby suppressing lipid accumulation; downregulates peroxisome proliferator-activated receptor γ (PPARγ), CCAAT/enhancer-binding protein α (C/EBPα), sterol regulatory element-binding protein 1c (SREBP1c), and fatty acid synthase (FAS); activates AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC); and inhibits mitogen-activated protein kinase (MAPK) and protein kinase B (Akt) signaling pathways in the subject.
5 . The method of claim 4 , wherein the non-alcoholic fatty liver is selected from hepatic steatosis or non-alcoholic steatohepatitis.
6 . A method of ameliorating non-alcoholic fatty liver, comprising;
administering a health functional food comprising Polygalin C as an active ingredient to a subject, wherein the Polygalin C inhibits differentiation of preadipocytes into adipocytes, thereby suppressing lipid accumulation; downregulates peroxisome proliferator-activated receptor γ (PPARγ), CCAAT/enhancer-binding protein α (C/EBPα), sterol regulatory element-binding protein 1c (SREBP1c), and the fatty acid synthase (FAS); activates AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC); and inhibits mitogen activated protein kinase (MAPK) and protein kinase B (Akt) signaling pathways in the subject.